Glucose control in the critically III

Contributions to Nephrology

Volumn 144, Issue , 2004, Pages 119-131

  Schetz, M ^a   Van Den Berghe, G ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

BLOOD CLOTTING DISORDER; CRITICAL ILLNESS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMMUNOPATHOLOGY; INFECTION; INFLAMMATION; INTENSIVE CARE UNIT; KIDNEY FAILURE; METABOLISM; NEUROLOGIC DISEASE; REVIEW; RISK FACTOR;

BLOOD COAGULATION DISORDERS; BLOOD GLUCOSE; CRITICAL ILLNESS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNE SYSTEM DISEASES; INFECTION; INFLAMMATION; INSULIN; INTENSIVE CARE UNITS; KIDNEY FAILURE; NERVOUS SYSTEM DISEASES; RISK FACTORS;

EID: 3343017583     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (65)

1. Thorell A, Nygren J, Ljungqvist O: Insulin resistance: A marker of surgical stress. Curr Opin Clin Nutr Met Care 1999;21:69-78.
2. McCowen KC, Malhotra A, Bistrian BR: Stress-induced hyperglycaemia. Crit Care Clin 2001;17:107-124.
3. Das UN: Is inslin an anti-inflammatory molecule? Nutrition 2001;17:409-413.
4. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-1367.
5. Mizock BA: Alterations in carbohydrate metabolism during stress: A review of the literature. Am J Med 1995;98:75-84.
6. Mizock BA: Alterations in fuel metabolism in critical illness: Hyperglycaemia. Best Pract Res Clin Endocrinol Metab 2001;15:533-551.
7. Grimble RF: Inflammatory status and insulin resistance. Curr Opin Clin Nutr Met Care 2002;5:551-559.
8. Marette A: Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Met Care 2002;5:377-383.
9. Van den Berghe G, de Zegher F, Bouillon R: Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 1998;83:1827-1834.
10. Pozzilli P, Leslie RD: Infections and diabetes: Mechanisms and prospects for prevention. Diabet Med 1994;11:935-941.
11. Funari AP, Zerr KJ, Grunkemeier GL, Starr A: Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999;67:352-360.
12. Rassias AJ, Marrin CA, Arruda J, Whalen PK, Beach M, Yeager MP: Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg 1999;88:1011-1016.
13. Nielson CP, Hindson DA: Inhibition of polymorphonuclear leukocyte respiratory burst by elevated glucose concentrations in vitro. Diabetes 1989;38:1031-1035.
14. Perner A, Nielsen SE, Rask Madsen J: High glucose impairs superoxide production from isolated blood neutrophils. Intens Care Med 2003;29:642-645.
15. Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H: Infection and diabetes: The case for glucose control. Am J Med 1982;72:439-450.
16. Black CT, Hennessey PJ, Andrassy RJ: Short-term hyperglycemia depresses immunity through nonenzymatic glycosylation of circulating immunoglobulin. J Trauma 1990;30:830-832.
17. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
18. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphony- lureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
19. Mukamal KJ, Nesto RW, Cohen MC, Muller JE, Maclure M, Sherwood JB, Mittleman MA: Impact of diabetes on long-term survival after acute myocardial infarction: Comparability of risk with prior myocardial infarction. Diab Care 2001;24:1422-1427.
20. Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Umans VA: Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol 2001;79:207-214.
21. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
22. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512-1515.
23. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H: Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J 1996;17:1337-1344.
24. Williams LS, Rotich J, Qi R, Fineberg N, Espay A, Bruno A, Fineberg SE, Tierney WR: Effects of admission hyperglycaemia on mortality and costs in acute ischemic stroke. Neurology 2002;59:67-71.
25. Rovlias A, Kotsou S: The influence of hyperglycaemia on neurological outcome in patients with severe head injury. Neurosurgery 2000;46:335-342; discussion 342-343.
26. Gore DC, Chinkes D, Heggers J, Herndon DN, Wolf SE, Desai M: Association of hyperglycemia with increased mortality after severe burn injury. J Trauma 2001;51:540-544.
27. Young B, Ott L, Dempsey R, Haack D, Tibbs P: Relationship between admission hyperglycemia and neurologic outcome of severely brain-injured patients. Ann Surg 1989;210:466-472.
28. Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R: Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999;84:1311-1323.
29. Baxter RC: Changes in the IGF-IGFBP axis in critical illness. Best Pract Res Clin Endocrinol Metab 2001;15:421-434.
30. Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P: Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003;31:359-366.
31. Gore DC, Chinkes DL, Hart DW, Wolf SE, Herndon DN, Sanford AP: Hyperglycemia exacerbates muscle protein catabolism in burn-injured patients. Crit Care Med 2002;30:2438-2442.
32. Mesotten D, Swinnen JV, Vanderhoydonc F, Wouters PJ, Van den Berghe G: Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 2004;89:219-226.
33. Mesotten D, Delhanty PJD, Vanderhoydonc F, Hardman KV, Weekers F, Baxter RC, Van den Berghe G: Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J Clin Endocrinol Metab 2002;87:5516-5523.
34. Donmoyer CM, Chen SS, Lacy DB, Pearson DA, Poole A, Zhang Y, McGuinnes OP: Infection impairs insulin-dependent hepatic glucose uptake during total parenteral nutrition. Am J Physiol 2003;284:E574-E585.
35. Taskinen MR: Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diab 2001;109:8180-8188.
36. Lanza-Jacoby S, Wong SH, Tabares A, Baer D, Schneider T: Disturbances in the composition of plasma lipoproteins during gram-negative sepsis in the rat. Biochim Biophys Acta 1992;1124:233-240
37. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C: Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000;181:8462-8472.
38. Carpentier YA, Scruel O: Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr Opin Clin Nutr Metab Care 2002;5:153-158.
39. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, Barie PS, Rubin AL: Low lipid concentrations in critical illness: Implications for preventing and treating endotoxemia. Crit Care Med 1996;24:584-589.
40. Kwiterovich PO: Lipoprotein heterogeneity: Diagnostic and therapeutic implications. Am J Cardiol 2002;90:1i-10i.
41. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C: The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993;76:1423-1427.
42. Tulenko TN, Sumner AE: The physiology of lipoproteins. J Nucl Cardiol 2002;9:638-649.
43. Harris HW, Grunfeld C, Feingold KR, Rapp JH: Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990;86:696-702.
44. Harris HW, Grunfeld C, Feingold KR, Read TE, Kane JP, Jones AL, Eichbaum EB, Bland GF, Rapp JH: Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993;91:1028-1034.
45. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G: Intensive insulin therapy exerts anti-inflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003;88:1082-1088.
46. Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality: A cohort analysis. JAMA 1996;275:1489-1494.
47. Metnitz PGH, Krenn CG, Steltzer H, Lang T, Ploder J, Lenz K, LeGall JR, Druml W: Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002;30:2051-2058.
48. de Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, Takala J, Sprung C, Cantraine F: Acute renal failure in the ICU: Risk factors and outcome evaluated by the SOFA score. Intens Care Med 2000;26:915-921.
49. Boulton AJ: Clinical presentation and management of diabetic neuropathy and foot ulceration. Diab Med 1991;8:S52-S57.
50. Hund E: Neurological complications of sepsis: Critical illness polyneuropathy and myopathy. J Neurol 2001;248:929-934.
51. Leijten FS, De Weerd AW, Poortvliet DC, De Ridder VA, Ulrich C, Harink-De Weerd JE: Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator. Intens Care Med 1996;22:856-861.
52. Bolton CF, Young GB: Critical Illness Polyneuropathy. Curr Treat Options Neurol 2000;2:489-498.
53. Bolton CF: Sepsis and the systemic inflammatory response syndrome: Neuromuscular manifestations. Crit Care Med 1996;24:1408-1416.
54. Weekers F, Giulietti A, Michalaki M, Coopmans W, Van Herck E, Mathieu C, Van den Berghe G: Metabolic, endocrine and immune effects of stress hyperglycaemia in a rabbit model of prolonged critical illness. Endocrinology 2003;in press.
55. Carr ME : Diabetes mellitus: A hypercoagulable state. J Diabetes Complications 2001;15:44-54.
56. Calles-Escandon J, Garcia-Rubi E, Mirza S, Mortensen A : Type 2 diabetes: One disease, multiple cardiovascular risk factors. Coron Artery Dis 1999;10:23-30.
57. Williams E, Timperley WR, Ward JD, Duckworth T: Electron microscopical studies of vessels in diabetic peripheral neuropathy. J Clin Pathol 1980;33:462-470.
58. Patrassi GM, Vettor R, Padovan D, Girolami A: Contact phase of blood coagulation in diabetes mellitus. Eur J Clin Invest 1982;12:307-311.
59. Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, Mariani G: Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992;67:643-654.
60. Hughes A, McVerry BA, Wilkinson L, Goldstone AH, Lewis D, Bloom A: Diabetes, a hypercoagulable state? Hemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol 1983;69:254-259.
61. Garcia Frade LJ, de la Calle H, Alava I, Navarro JL, Creighton LJ, Gaffney PJ: Diabetes mellitus as a hypercoagulable state: Its relationship with fibrin fragments and vascular damage. Thromb Res 1987;47:533-540.
62. Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, Mariani G: Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992;67:643-654.
63. Vukovich TC, Schernthaner G: Decreased protein C levels in patients with insulin-dependent type I diabetes mellitus. Diabetes 1986;35:617-619.
64. Garcia Frade LJ, Landin L, Avello AG, Martin Yerro J, Navarro JL, Creighton LJ, Gaffney PJ: Changes in fibrinolysis in the intensive care patient. Thromb Res 1987;47:593-599.
65. Mavrommatis AC, Theodoridis T, Economou M, Kotanidou A, El Ali M, Christopoulou-Kokkinou V, Zakynthinos SG: Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: Comparison with severe sepsis and septic shock. Intens Care Med 2001;27:1853-1859.